Healthcare Industry News: HSMN NewsFeed
News Release - April 23, 2019
Vetoquinol USA Launches Flexprofen(TM)Generic carprofen chewable tablet developed to treat osteoarthritis symptoms in dogs
FORT WORTH, Texas, April 23, 2019 -- (Healthcare Sales & Marketing Network) -- Vetoquinol USA, a world-class developer of veterinarian-approved formulas for animal healthcare products, today announced the launch of its newest product called Flexprofen™.
Flexprofen™ is a generic, beef-flavored chewable tablet that contains carprofen, which is the most widely-used and clinically-proven non-steroidal anti-inflammatory (NSAID) used in veterinary medicine. The product is high-quality and comparable to the leading brand name carprofen chewables that address symptoms of pain and inflammation typically associated with osteoarthritis. Flexprofen™ can also be used to treat dogs with postoperative pain resulting from soft tissue and orthopedic surgeries.
"Osteoarthritis and joint care are a key strategic therapeutic target, not only for Vetoquinol USA, but for Vetoquinol globally," said Eric Alsup, Country Manager at Vetoquinol USA. "We are very pleased to have the opportunity to expand our osteoarthritis platform with the addition of Flexprofen™, a true chewable carprofen tablet that will enhance our existing offering of carprofen caplets, carprofen flavored tablets and our joint supplement line."
Flexprofen™ is scored for easy dosing and available in 25 milligrams, 75 milligrams, and 100 milligrams of carprofen per chewable in 180 count bottles. The recommended dosage for oral administration to dogs is 2 milligrams per pound of body weight daily, which may also be divided and administered as 1 milligram per pound twice daily. For the control of postoperative pain, administer approximately 2 hours before the procedure. For additional prescribing information, click here.
To learn more about Vetoquinol USA and all of its oral carprofen options, visit www.vetoquinolusa.com. You can also follow on Facebook for information on animal health and care.
About Vetoquinol USA
Headquartered in Fort Worth, Texas, Vetoquinol USA is owned by Vetoquinol SA, an independent, family-owned French pharmaceutical company founded in 1933. Dedicated exclusively to animal health, Vetoquinol USA is focused on the development, production and marketing of FDA, EPA and AAFCO-regulated pharmaceutical, nutritional and dermatological products for small and large animals. For more information, visit www.vetoquinolusa.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.